Dyne Therapeutics Files 8-K on Material Definitive Agreement

TL;DR

**Dyne Therapeutics reported a material agreement, but the filing is light on details.**

AI Summary

Dyne Therapeutics, Inc. filed an 8-K on January 4, 2024, to report an "Entry into a Material Definitive Agreement" and "Other Events." While the filing indicates a significant agreement was made, the specific details of this agreement, including names, dollar amounts, or the nature of the transaction, are not disclosed within the provided text. This matters to investors because without the specifics, it's impossible to assess the potential positive or negative impact of this material agreement on Dyne Therapeutics' future operations, financial health, or stock value.

Why It Matters

This filing signals a significant corporate event for Dyne Therapeutics, but the lack of specific details makes it difficult for investors to understand its implications for the company's future prospects.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement but provides no specifics, creating uncertainty for investors regarding its potential impact.

Analyst Insight

A smart investor would await further disclosures from Dyne Therapeutics regarding the specifics of this material definitive agreement to understand its financial and operational implications before making any investment decisions.

Key Players & Entities

• Dyne Therapeutics, Inc. (company) — the registrant filing the 8-K
• Nasdaq Global Select Market (company) — where Dyne Therapeutics' common stock is registered

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common stock, $0.0001 par value per share DYN Nasdaq Glob
• $17.50 — ing price of the Underwritten Shares is $17.50 per share, and the Underwriters have ag
• $16.45 — he Underwriting Agreement at a price of $16.45 per share. Under the terms of the Under
• $281.6 m — from the Offering will be approximately $281.6 million, or approximately $323.9 million
• $323.9 million — mately $281.6 million, or approximately $323.9 million if the Underwriters exercise in full th

Filing Documents

• d110504d8k.htm (8-K) — 33KB
• d110504dex11.htm (EX-1.1) — 215KB
• d110504dex51.htm (EX-5.1) — 10KB
• d110504dex991.htm (EX-99.1) — 9KB
• g110504g0105100056224.jpg (GRAPHIC) — 3KB
• g110504g0105110044970.jpg (GRAPHIC) — 2KB
• g110504g0105110045220.jpg (GRAPHIC) — 7KB
• 0001193125-24-002892.txt ( ) — 470KB
• dyn-20240104.xsd (EX-101.SCH) — 3KB
• dyn-20240104_lab.xml (EX-101.LAB) — 18KB
• dyn-20240104_pre.xml (EX-101.PRE) — 11KB
• d110504d8k_htm.xml (XML) — 3KB

01. Entry Into a Material Definitive Agreement

Item 1.01. Entry Into a Material Definitive Agreement. On January 4, 2024, Dyne Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering (the "Offering") of 17,150,000 shares (the "Underwritten Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"). All of the Underwritten Shares are being sold by the Company. The public offering price of the Underwritten Shares is $17.50 per share, and the Underwriters have agreed to purchase the Underwritten Shares from the Company pursuant to the Underwriting Agreement at a price of $16.45 per share. Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option, exercisable for 30 days from the date of the Underwriting Agreement, to purchase up to an additional 2,572,500 shares of Common Stock (the "Option Shares" and together with the Underwritten Shares, the "Shares") at the public offering price less the underwriting discounts and commissions. The Company estimates that the net proceeds from the Offering will be approximately $281.6 million, or approximately $323.9 million if the Underwriters exercise in full their option to purchase the Option Shares, in each case, after deducting underwriting discounts and commissions and estimated offering expenses. The Shares will be issued pursuant to a prospectus supplement dated January 4, 2024, and an accompanying base prospectus that form a part of the registration statement on Form S-3 that the Company filed with the Securities and Exchange Commission (the "SEC") on November 4, 2021 (File No. 333-260755) and was declared effective by the SEC on November 17, 2021 and a related registration statement that was filed with the SEC pursuant to Rule 462(b) of the Secu

01. Other Events

Item 8.01. Other Events. Pricing of Public Offering The full text of the press release issued on January 4, 2024, announcing the pricing of the Offering is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Cash Runway The Company believes that the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities, will enable the Company to fund its operating expenses and capital expenditure requirements through 2025. The Company has based its estimates on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including the anticipated net proceeds from the Offering, the anticipated closing date of the Offering and the Company's anticipated cash runway, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties rel

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated January 4, 2024, by and among the Company and Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein. 5.1 Opinion of Wilmer Cutler Pickering Hale and Dorr LLP 23.1 Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1 above) 99.1 Press Release of Dyne Therapeutics, Inc., dated January 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DYNE THERAPEUTICS, INC. Date: January 5, 2024 By: /s/ Joshua Brumm Name: Joshua Brumm Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR